The hematologic disorders in patients with acute cardioembolic stroke are not fully understood, and no reliable measures are available to identify patients at high risk for recurrent embolism. We analyzed coagulation and fibrinolytic functions in 22 patients with cardiogenic cerebral embolism ^24 hours after onset and in 25 age-matched controls. The levels of antithrombin HI, protein C, and a^-plasmin inhibitor were significantly lower in the patients than in the controls (/?<0.001, 0.02, and 0.05, respectively). In contrast, the plasma concentrations of thrombinantithrombin i n complex and crosslinked D-dimer were markedly higher in the patients than in the controls (p<0.01 and 0.001, respectively). At the time of admission, the plasma concentrations of thrombin-antithrombin III complex and crosslinked D-dimer in the eight patients at high risk for recurrent embolization (one with prodromal embolism, three with intracardiac thrombi, and four with recurrent embolization) were 2.8 and 3.5 times, respectively, higher than those in the 14 patients without recurrence or thrombus formation. The lowest concentration of crosslinked D-dimer in the eight patients at high risk for recurrent embolization was 600 ng/ml on admission. Our results suggest that patients with acute cardioembolic stroke have various degrees of consumption coagulopathy and that the plasma concentrations of thrombin-antithrombin HI complex and crosslinked D-dimer can be useful indicators of those who are prone to recurrent embolization during this stage. (Stroke 1991^2:12-16)
C
ardioembolic stroke is one of the most critical, and often catastrophic, complications in patients with cardiac disorders. Patients with cardioembolic stroke may also suffer from early recurrent embolization. 1 - 4 Anticoagulant therapy has been applied prophylactically against subsequent thromboembolism, 1 -3 but its efficacy has been questionable, mainly because of hemorrhagic complications including hemorrhagic transformation of the infarct. 1 - 5 A means of identifying embolism-prone patients (those with either an initial or an early recurrent attack) immediately after stroke would be of great value in clinical practice.
The pathophysiology of intracardiac thrombus formation has remained obscure mainly because of the difficulty in collecting blood samples before the onset of cardioembolic stroke and the complexity of hematologic conditions such as subsequent interference of coagulation and fibrinolytic reactions following stroke. 6 - 7 It is evident that the earliest sampling of blood after onset most accurately reflects the hemostatic conditions of cardioembolic events. In our previous paper, 8 we suggested that consumption coagulopathy is present in patients with acute cerebral embolism. The purpose of our present study was to clarify using presently available parameters the hematologic disorders in patients with acute cardioembolic stroke.
Subjects and Methods
Blood samples were taken from 22 consecutive patients with acute cardioembolic stroke (15 men and seven women, aged 31-78 [average 64.7] years) who were admitted to the Stroke Care Unit of the National Cardiovascular Center ^24 hours after onset. Patients were diagnosed as having cardioembolic stroke when they were confirmed to have a potential cardiac source of emboli by two-dimensional echocardiography (2D-echo) or electrocardiography. Brain computed tomography and cerebral angiography were performed to confirm the presence of characteristic findings for embolic stroke.
1 ' 910 Duplex ultrasonography was performed to exclude carotid lesions in patients with contraindications for angiography. Cerebral angiography was performed in 17 patients (77.3%). The absence of atherosclerotic changes such as ulcerative plaques in the aortic arch and cerebral arteries were also confirmed angiographically in all patients with nonvalvular atria! fibrillation to exclude artery-to-artery embolism.
1 A 2D-echo study was performed on all patients as soon as possible after admission, and 2D-echo was repeated as frequently as possible. Electrocardiograms were continuously monitored for >7 days after admission to detect transient arrhythmias.
Patients with a history of myocardial infarction or angina pectoris ^6 months before the cardioembolic stroke were excluded since some hematologic abnormalities are reported to be associated with acute coronary artery disease. 1112 Patients who were receiving anticoagulants or platelet antiaggregant agents and those with liver dysfunction, renal dysfunction, or any type of malignancy were also excluded.
The age-matched controls consisted of 25 healthy men with an average age of 61 years. No control had a medical history of cardiovascular, cerebrovascular, or peripheral vascular diseases or any other major medical illness.
Blood samples were obtained ^24 hours after onset and before cerebral angiography and the initiation of therapy in the patients. Venous blood was taken from the antecubital vein of the nonparafyzed arm using the two-syringe technique. No patient had ongoing venous thrombosis at the time of sampling. After discarding the first 3 ml, blood was collected into a siliconized glass tube that contained one-tenth volume of 3.8% trisodium citrate. Plasma was separated by centrifugation at 2,300g for 15 minutes at room temperature and stored at -70°C until use. Blood samples were obtained similarly in the controls.
The plasma levels of antithrombin III, protein C, plasminogen, and a 2 -plasmin inhibitor were measured by the amidolytic method. 13 - 16 Plasma concentrations of thrombin-antithrombin III complex and crosslinked D-dimer were determined using commercially available enzyme-linked immunosorbent assay kits (Behringwerke A.G., Marburg, F.R.G. 17 and MAbCO, Springwood, Australia respectively). 18 Student's two-tailed unpaired t test was used for statistical analysis, and the correlation coefficient (r) was calculated. Table 1 . Blood sampling was performed s8 hours after onset in approximately three fourths. Underlying cardiac disorders were rheumatic heart disease in eight, cardiomyopathy in two, previous myocardial infarction in three, and nonvalvular atrial fibrillation in nine. No intracardiac thrombi were detected with 2D-echo in any patient at the time of admission. In three patients (cases 7, 11, and 21), however, intracardiac thrombi appeared on day 14, 10, and 4, respectively. A history of systemic embolism was present in six patients (27.3%); one patient (case 4) experienced a prodromal cardioembolic transient ischemic attack and embolization to the right leg 61 and 22 hours before the stroke, respectively, but the other five patients had no recent events. Immediate anticoagulation was not performed except in one patient (case 4). Before the commencement of chronic anticoagulation, recurrent embolization occurred in four patients (cases 2, 16,17, and 20) on day 3, 58, 9, and 19, respectively. No further recurrence was observed in these patients after anticoagulation.
Results

Characteristics of the 22 patients are summarized in
Results of the hematologic studies are shown in Table 2 . The levels of antithrombin III, protein C, and a 2 -plasmin inhibitor were significantly lower in the patients than in the controls. However, there was no significant difference in the plasminogen levels between the groups. On the contrary, the concentrations of thrombin-antithrombin III complex and crosslinked D-dimer were markedly greater in the patients than in the controls. Among these parameters, only the concentrations of thrombin-antithrombin III complex and crosslinked D-dimer showed good correlation (r=0.76, /?<0.01, 7=0.02^-1-1.52; Figure 1 ).
Eight patients who later developed recurrent embolism (cases 2,16,17, and 20) or intracardiac thrombi (cases 7, 11, and 21) or who had experienced prodromal embolism (case 4) were regarded to be at high risk for recurrent embolization (high-risk subgroup) since persons having intracardiac thrombi are reported to have a much higher risk for embolization than those without. 19 The remaining 14 patients who never had recurrent embolism or formation of intracardiac thrombi were regarded to be at low risk for recurrent embolization (low-risk subgroup). Hematologic data of the two subgroups are shown in Table 3 . Although the concentrations of procoagulant factors and inhibitors did not differ significantly, the concentrations of both thrombin-antithrombin III complex and crosslinked D-dimer were significantly higher in the high-risk than in the low-risk subgroup. In all members of the high-risk subgroup, the plasma levels of crosslinked D-dimer were ^600 ng/ml (Figure 1 ). These two markers showed excellent sensitivities, but the specificity of thrombin-antithrombin III complex was inferior to that of crosslinked D-dimer (Table 3) .
Discussion
We observed a marked increase in the concentrations of both thrombin-antithrombin III complex and crosslinked D-dimer in patients with acute cardioembolic stroke. Our results indicate that ongoing activation of coagulation and subsequent fibrinolytic reactions may exist at the time of embolization.
1718^0
Modest but significant decreases in the concentrations of antithrombin III and protein C in the patients also suggest that these procoagulant inhibitors may have been consumed during intracardiac thrombus formation. Excess thrombin that was not completely inactivated by antithrombin III further generated excess fibrin, which, in turn was split by plasmin, giving rise to crosslinked D-dimer with consumption of a 2 -plasmin inhibitor. However, except for a significant relation between thrombin-antithrombin III complex and crosslinked D-dimer (r=0.76), the concentrations of these markers did not correlate closely. Therefore, patients with cardioembolic stroke appear to be in the hypercoagulable state consistent with a low-grade consumption coagulopathy.
The concentration of thrombin and the subsequent level of plasmin generation in our patients with acute cardioembolic stroke were consistent with a lowgrade consumption coagulopathy such as chronic disseminated intravascular coagulation.
20
- 21 It should be noted, however, that the change in concentrations of hematologic markers in patients with cardioembolic stroke reflects local (intracardiac) derangement of the coagulation process, but not systemic abnormalities, because other systemic diseases were not pres- ent in these patients. In our previous paper, 8 we suggested that consumption coagulopathy is present in patients with acute cerebral embolism. However, the pathophysiologic mechanisms of intracardiac thrombus formation are still obscure, while alteration of the cardiac valves, atrial wall, or endocardium and stasis within a dilated, fibrillating left atrium are possible triggers for the initiation of hematologic disorders. In patients with rheumatic heart disease at high risk for thromboembolism, increased concentrations of /3-thromboglobulin, 23 have been reported. Such results suggest that a low-grade consumption coagulopathy exists in patients at high risk for thromboembolism, which is consistent with our findings, although the underlying cardiac disorders were not uniform in our series.
Patients at high risk for recurrent embolization had markedly higher levels of thrombin-antithrombin III complex and crosslinked D-dimer than lowrisk patients at the time of hospital admission. On the contrary, the concentrations of antithrombin III and protein C did not differ between the subgroups. These results suggest that degradation products such as thrombin-antithrombin III complex and crosslinked D-dimer are more sensitive than procoagulant factors and inhibitors for the detection of modest alterations of the hypercoagulable state. Prolonged hematologic derangement after the first episode (i.e., long-lasting hypercoagulability) might be one trigger for recurrent embolization. Another possibility is that a more exuberant fibrinolytic response exists in those patients at high risk for recurrence.
The levels of thrombin-antithrombin III complex and crosslinked D-dimer in patients with acute cardioembolic stroke can be useful in identifying those at high risk for early recurrent embolism since no other reliable measure is currently available. Although factors initiating this hypercoagulable state in patients with acute cardioembolic stroke are still uncertain, they appear to have characteristics of a consumption coagulopathy. Not only immediate anticoagulation, but also the administration of antithrombin III or protein C, may be effective in preventing early recurrent embolization. Our results encourage the hope that prediction may be possible. Further controlled studies are needed to determine the value of measuring plasma concentrations of crosslinked D-dimer or thrombin-antithrombin III complex for predicting early recurrent embolization.
